MacroGenics legal chief sells 31K shares

MACROGENICS INC (MGNX) reported that officer Jeffrey Stuart Peters, Senior VP, GC, and Secretary, sold 31,105 shares of common stock on 2026-08-19 in an open-market or private transaction.

Rhea-AI Filing Summary

MACROGENICS INC (MGNX) reported that officer Jeffrey Stuart Peters, Senior VP, GC, and Secretary, sold 31,105 shares of common stock on 2026-08-19 in an open-market or private transaction. The sale, effected under a Rule 10b5-1 trading plan adopted on May 20, 2026, was executed in multiple trades at prices ranging from $4.12 to $4.24 per share, with a reported per-share price of $4.15. Following this transaction, Peters reported holding 0 shares of MacroGenics common stock directly.

Insider Trade Summary 10b5-1

Net Seller: 31,105 shares

Net Sell 1 txn

Insider Peters Jeffrey Stuart

Role Senior VP, GC, and Secretary

Sold 31,105 shs ($129K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	31,105	$4.15	$129K

Holdings After Transaction: Common Stock — 0 shares (Direct)

Footnotes (2)

1. F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 20, 2026.
2. F2. This transaction was executed in multiple trades at prices ranging from $4.12 to $4.24. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Key Figures

Shares sold: 31,105 shares of Common Stock Reported transaction price: $4.15 per share Trade price range: $4.12–$4.24 per share +2 more

5 metrics

Shares sold 31,105 shares of Common Stock Non-derivative sale on 2026-08-19 by officer Jeffrey Stuart Peters

Reported transaction price $4.15 per share Per-share price reported for the 31,105-share sale

Trade price range $4.12–$4.24 per share Multiple trades executed within this range on 2026-08-19

Shares owned after transaction 0 shares Direct common stock holdings reported following the sale

Rule 10b5-1 plan adoption date May 20, 2026 Date the reporting person adopted the trading plan used for these sales

Key Terms

Rule 10b5-1 trading plan, open market or private transaction, non-derivative

3 terms

Rule 10b5-1 trading plan regulatory

"The sales reported ... were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open market or private transaction market

"transaction_code_description: Sale in open market or private transaction"

non-derivative financial

"transaction_type: non-derivative"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did MGNX disclose in this Form 4?

MacroGenics disclosed that officer Jeffrey Stuart Peters sold 31,105 shares of common stock on 2026-08-19 in an open-market or private transaction, reporting a per-share price of $4.15 and post-transaction direct holdings of 0 shares.

At what prices were the MGNX shares sold by Jeffrey Stuart Peters?

The 31,105 MacroGenics shares were sold in multiple trades at prices ranging from $4.12 to $4.24 per share. The Form 4 reports a per-share transaction price of $4.15, with additional detail available upon request from the company or the SEC staff.

Did the MGNX insider sale occur under a Rule 10b5-1 trading plan?

Yes. The Form 4 states the sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Jeffrey Stuart Peters on May 20, 2026, indicating the trades were pre-arranged under that plan.

How many MGNX shares does Jeffrey Stuart Peters hold after this transaction?

After the reported sale, Jeffrey Stuart Peters reported direct ownership of 0 shares of MacroGenics common stock. The Form 4 does not list any remaining direct common stock holdings for him.

What is the role of Jeffrey Stuart Peters at MACROGENICS INC (MGNX)?

Jeffrey Stuart Peters is identified as an officer of MacroGenics, serving as Senior VP, GC, and Secretary. His Form 4 reports his status as an officer but not as a director or 10% owner.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/20/2026 - 06:19 PM EDT Accepted by SEC EDGAR 08/20/2026 - 06:19 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Peters Jeffrey Stuart

(Last) (First) (Middle)

9704 MEDICAL CENTER DRIVE

(Street)

ROCKVILLE MARYLAND 20850

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MACROGENICS INC [ MGNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Senior VP, GC, and Secretary

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/19/2026		S(1)		31,105	D	$4.15(2)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 20, 2026.

2. This transaction was executed in multiple trades at prices ranging from $4.12 to $4.24. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Remarks:

	/s/ Beth A. Smith, Attorney-in-fact	08/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)